Literature DB >> 7908983

Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals.

A Ahmad1, R Morisset, R Thomas, J Menezes.   

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is an important antiviral effector mechanism. However, its role, as well as the functional integrity of the ADCC-effector cells in HIV infections, is not well understood. For studying gp120/41-specific ADCC, we recently developed a virus-free target cell system, using a natural killer (NK) cell activity-resistant human lymphoid cell line of B lineage, which was transfected with the env gene of the human immunodeficiency virus type 1 (HIV-1); gp120/41-expressing cell clones were thus selected. In this study, these gp120/41-expressing cloned cells were used as targets in a gp120/41-specific ADCC assay for (a) examining the functional integrity of ADCC-effector cells from HIV-seropositive individuals, and (b) titrating the sera of these individuals for gp120/41-specific, ADCC-mediating antibodies. Our data indicate for the first time that the percentage of sera positive for ADCC-mediating antibodies to gp120/41 is higher in individuals with CD4 counts < or = 400 and > or = 200/mm3. The individuals with CD4 counts < 200/mm3 were found to have the lowest titers of these antibodies in their sera. The ADCC-effector function of the peripheral blood mononuclear cells (PBMC) of HIV-infected individuals was significantly (p < 0.05) reduced as compared to the PBMC from healthy, HIV-seronegative individuals. Further, human recombinant IL2 and interferon-gamma were found to exert a significant (p < 0.05) enhancing effect on ADCC mediated by PBMC from these HIV-infected individuals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908983

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  26 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Accumulation of Cytotoxic CD16+ NK Cells in Simian Immunodeficiency Virus-Infected Lymph Nodes Associated with In Situ Differentiation and Functional Anergy.

Authors:  Jamie L Schafer; Haiying Li; Tristan I Evans; Jacob D Estes; R Keith Reeves
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 3.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

4.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Authors:  Anne-Sophie Dugast; Leonidas Stamatatos; Andrew Tonelli; Todd J Suscovich; Anna F Licht; Iliyana Mikell; Margaret E Ackerman; Hendrik Streeck; P J Klasse; John P Moore; Galit Alter
Journal:  Eur J Immunol       Date:  2014-08-11       Impact factor: 5.532

7.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

Review 8.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

9.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.

Authors:  Donald N Forthal; Gary Landucci; Bhavna Chohan; Barbra A Richardson; R Scott McClelland; Walter Jaoko; Catherine Blish; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.